For years patients from depression have been cycled through one drug after the next, a hit-and-miss approach that also reflects the poor odds of success in clinical development. But now investigators say that a trial of a well-known anesthetic often used illicitly in the club scene has real potential in the fight against depression.
Grifols has agreed to foot up to $65 million of the Phase III bill, with a promise of $25 million in development milestones for a successful outcome. And Grifols is buying up a 35% stake in Aradigm at a cost of $26 million.
With one likely blockbuster on the market in Eylea and at least three others in development, Regeneron Chief Scientific Officer Dr. George Yancopoulos has plenty to keep him busy for the next several years. Read the full feature >>
Bayer has a new set of upbeat results from its long-term extension study of riociguat, a major new player in a busy field of competitors angling for a share of the market for pulmonary arterial hypertension.
Pfizer says inotuzumab failed a Phase III study for aggressive CD22+ non-Hodgkin's lymphoma. The monitoring committee concluded that inotuzumab in combination with rituximab was not going to deliver the data needed on overall survival.
Shares of XenoPort skidded lower this morning after the biotech announced its lead experimental drug had decisively failed a late-stage study for spasticity triggered by multiple sclerosis. The troubled biopharma company, which has been struggling to spur sales for the approved drug Horizant for restless leg syndrome, immediately opted to bury the program.
In a Friday announcement, Novo Nordisk said it completed the first phase III trial of its drug N9-GP for hemophilia B patients.
The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become enlarged as a result of abnormal blood cell production.
Gilead may be best known for its HIV drug franchise and a stellar late-stage effort on the hepatitis C front, but the big biotech is also making an ambitious bid to rapidly build a portfolio of cancer drugs. And last night Gilead captured a bit of the ASCO limelight with positive data from a small, early-stage study of the leukemia drug idelalisib (GS-1101).
Roche got a big boost for its bid to position the leukemia drug GA101 (obinutuzumab) as a next-gen successor to its blockbuster Rituxan, posting late-stage data last night that showed that a combination with chemotherapy performed much better than chemo alone or in combination with Rituxan.